Efficacy and safety of topical mometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01%in vitiligo

Authors

  • Shad Muhammad Wazir
  • Muhammad Majid Paracha
  • Sami Ullah Khan

Keywords:

Vitiligo, mometasone furoate, tacrolimus

Abstract

Objectives To compare the efficacy and safety of topicalmometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01% in vitiligo. Patients and methods This interventional, quasi-experimental study was conducted at Department of Dermatology, Lady Reading Hospital, Peshawar, from January, 2008 to August, 2008. Patients were selected by non-probability purposive sampling method after obtaining an informed consent. Sixty patients of vitiligo (26 male and 34 female), aged older than five years and involving less than 30% of body surface area were enrolled. All the patients were randomly divided into two equal groups using random number table. Group I patients were treated with twice daily application of topical mometasone furoate 0.01%, whereas those of group II were advised to apply mometasone plus tacrolimus ointment on the lesions twice daily. The patients were followed up weekly for first month and later on fortnightly for five months to monitor the improvement and adverse effects. Results Tacrolimus plus mometasone was effective (grade 4-5) in 70% of patients whereas topical mometasone alone was effective (grade 4-5) in none of the patients. The results of combination therapy were much better than mometasone alone. The combination therapy was also more effective in type Π and type Ш skin than type IV skin. No side effects were observed in two groups. Conclusion We recommend that topical mometasone has no role in the treatment of vitiligo in type IV skin but when combined with tacrolimus may potentiate its efficacy. 

References

Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998; 38:647-666.

Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001; 144: 55-65.

Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol Clin 2000; 18: 79-88.

Khalid M. Vitiligo. Clinical features and treatment (Dissertation). Karachi: College of Physicians and Surgeons Pakistan, 1993: 1-2.

Qureshi AA, Qureshi AS, Shah SA. Vitiligo. J Pak Assoc Dermatol 1992; 2: 1-16.

Noor SM. Quality of life in vitiligo patients (Dissertation). Karachi: College of Physicians and Surgeons Pakistan, 2000:3-4.

Tonsi A. Vitiligo and its management update: a review. Pak J Med Sci 2004; 20: 242-7.

Lan CC, Chen GS, Chiou MH et al. FK506 promotes melanocytes and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanism of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-5.

Njoo MD, Spuls PI, Bos JD et al. Nonsurgical repigmentation therapies in vitiligo. Arch Dermatol 1998; 134: 1532-40.

Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000; 42: 245-53.

Lepe V, Moncada B, Castanedo-Cazares JP et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.

Almeida P, Borrego L, Rodriguez-Lopez J et al. Vitiligo. Treatment of 12 cases with topical tacrolimus. Actas Dermosifiliogr 2005: 96: 159-63.

Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.

Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4.

Downloads

Published

2016-12-21

How to Cite

1.
Wazir SM, Paracha MM, Khan SU. Efficacy and safety of topical mometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01%in vitiligo. J Pak Assoc Dermatol [Internet]. 2016Dec.21 [cited 2024Nov.8];20(2):89-92. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/427

Issue

Section

Original Articles